GE HealthCare announced CE Mark for its next-generation Omni 128cm total body positron emission tomography / computed tomography (PET/CT) system, a major milestone in its mission to advance… read more.
Summary Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings… read more.
Guardant Health Inc announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based screening test demonstrates patient adherence of 95% in screening… read more.
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new and updated data for CAR T-cell therapy candidate, GLPG51011, at the 67th American Society of… read more.
Bavarian Nordic A/S announced the award of a joint procurement contract by the European Commission, through the Health Emergency Preparedness and Response Authority (HERA), enabling the EU, its… read more.
Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer’s disease pathology in symptomatic patients, supporting diagnosis, according to a new study in Neurology Clinical Practice,… read more.
Johnson & Johnson MedTech announced advancements in developing the company’s robotics systems with physical artificial intelligence (AI) technologies that create simulated environments to accelerate future product innovation, optimize… read more.
Novartis will present new data from 34 abstracts across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin (October 17-21, 2025). “We… read more.
Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio announced that Phio Pharmaceuticals is a presenting… read more.
Novartis announced positive results from V-DIFFERENCE, a Phase IV study evaluating Leqvio (inclisiran) compared to placebo, both administered on top of individually optimized lipid-lowering therapy (LLT), in patients… read more.
Bristol Myers Squibb announced the presentation of new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 29 –… read more.
Alkermes announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at World Sleep Congress, taking place… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
